Study of therapeutic results, lymph node ratio, short-term and long-term complications of lateral lymph node dissection in rectal cancer patients

Habibollah Mahmoodzadeh1, Ramesh Omranipour1, Anahita Borjian1, Mohammad Amin Borjian1

1 Tehran University of Medical Science, Cancer Institute, Tehran, Iran

ABSTRACT

Objective: This study aimed to assess disease free survival, lymph node ratio (LNR) and complication rate among advanced mid to low rectal cancer patients (stage 2-3) who underwent total mesorectal excision (TME) and lateral lymph node dissection (LLND) at the Iran Cancer Institute in 2016-2018.

Material and Methods: The study was carried out on 32 patients treated by curative surgery and lateral lymph node dissection at the Iran Cancer Institute from 2016 March to 2018 March. Chi-square test was used to assess the distribution of dichotomous clinical outcomes by sex. We also used Breslow test in Kaplan-Meier approach to estimate 1-year disease free survival and corresponding 95% confidence intervals (CI).

Results: Of the 279 dissected lymph nodes by TME, 42 nodes (in mesorectal) and of the 232 dissected lymph nodes by LLND, 7 nodes (in iliac, para-iliac and obturator) were positive for metastasis. Higher local recurrence was observed in men (three patients) compared to women (one patient) which was not statistically significant (p= 0.878). We also observed higher 1-year disease free survival rate in women (1-year disease free survival= 93.3%) compared to men (1-year disease free survival= 82.4%), which also was not statistically significant (p= 0.356). 1-year disease free survival rate in patient with negative lymph nodes was 95.5% while respective number in patients with positive lymph nodes was 70% (p= 0.047).

Conclusion: TME with LLND could prolong survival and reduce local recurrence in patients with advanced low rectal cancer. However, large-scale clinical trials are required to evaluate such procedure as a standard in Iran.

Keywords: Rectal neoplasms, lymph node excision, survival, chemoradiotherapy

INTRODUCTION

Total mesorectal excision (TME) is known as the standard treatment for advanced low rectal carcinoma. It is reported that adoption of TME could be of benefit for patients with low rectal carcinoma (1-3). TME could decrease local recurrence and increase survival. Previous studies have supported the effectiveness of TME. However, it is reported that 5-40% of low rectal cancer patients having undergone this technique experience local recurrence after surgery and prognosis in such patients still remains poor (4-6).

It is supposed that poor prognosis of low rectal carcinoma is mainly due to metastasis of lymph nodes outside of the TME field (6-8). Dissection of lateral pelvic lymph nodes is a complementary approach that can be considered as an important fact or to reduce local recurrence and extending low rectal cancer patients’ survival. This hypothesis has been investigated in several studies. However, the role of lymph node dissection in terms of prolonging survival of advanced case of low rectal carcinoma is still disputed. In some studies lateral lymph node dissection (LLND) has not depicted survival benefit for low rectal cancer patients, while more recent large scale researches provided supporting evidence for the benefit of LLND (9,10).

In the current study it was aimed to assess disease free survival, LNR and complication rate among advanced low and middle rectal cancer patients who underwent TME and lateral lymph node dissection at Iran Cancer Institute.

MATERIAL and METHODS

The current research was a case-series study, carried out on 32 eligible patients with advanced stages of lower and mid-rectal cancer (stage 2 and 3) who were treated by
TME plus LLND at the Iran Cancer Institute. The eligibility criteria included: All patients with stage 2 and 3 of lower and mid-rectal cancer, referring to Iran Cancer Institute from 2016 March to 2018 March who agreed to participate in our study. The exclusion criteria included: metastatic, high rectal and rectosigmoid cancers and unwillingness to participate in the study. The methodology of the study was reviewed and approved by the medical ethics committee of Tehran University of Medical Science (Approval ID: IR.TUMS.VCR.REC.1397.629-Certificate available on demand). Before the study, we assessed whether the patients were eligible to perform LLND according to physical examination, colonoscopy and abdominopelvic and thoracic computed tomography (CT) as a metastasis workup. Prior to study initiation, a written informed consent, addressing that patients could exit the study at any desired time, without negative impact on their future treatment procedure, was completed by each one of them.

In the study group, all patients received chemoradiotherapy as neoadjuvant treatment. All surgical operations were performed using standard open laparotomy with mid-line incision. In the LLND technique, bilateral extraction of para-iliac and obturator lymph nodes was performed (from iliac artery bifurcation to obturator nerve). In order to minimize post-operative complications, complete neurovascular and ureteral exploration was performed for all patients. After surgery, we counted the number of total dissected and positive lymph nodes to estimate LNR. All study participants were actively followed-up for 1 year after surgery and in each post-op examination, we looked for local recurrence, sexual and urinary disorders and death.

Chi-Square test was used to assess the distribution of clinical outcomes by sex. We also reported mean and standard deviation (SD) for continuous investigated variables. Additionally, to calculate disease-free survival in patients with advanced low and middle rectal cancer, Breslow (Generalized Wilcoxon) test was used in Kaplan-Meier approach. All statistical analyses were performed by IBM® SPSS® (Version 22.0.0.0).

RESULTS

Overall, the current study investigated 32 patients with advanced low and middle rectal cancer treated with TME plus LLND at the Iran Cancer Institute, of whom 17 were males and 15 were females. Mean age of the participants was 57.3 (± 13.9) years. Total numbers of dissected lateral lymph nodes by TME and LLND were 279 and 232, respectively. Of the 279 dissected lymph nodes by TME, 42 nodes (in mesorectal) and of the 232 dissected lymph nodes by LLND, seven nodes (in iliac, para-iliac and obturator) were positive for metastasis (Table 1).

In the first year following surgery, for each studied patient, carcinoembryonic antigen (CEA) level was screened every three months. At the end of the first year, colonoscopy and double-contrast thoraco-abdomino-pelvic CT scan was performed on all of the studied patients. In general, lymph node dissection associated complications was observed in one male patient with impotency. Respective number was 0 in females (p= 0.910). Higher local recurrence was observed in men (three patients) compared to women (one patient) which was not statistically significant (p= 0.878). We also observed higher 1-year disease free survival rate in women (93.3%) compared to men (82.4%), which again, was not statistically significant (p= 0.356). In addition, 1-year disease free survival was calculated for patients with negative and positive lateral lymph nodes. 1-year disease free survival rate in patient with negative lymph nodes was 95.5% while respective number in patients with positive lymph nodes was 70% (p= 0.047) (Figure 1). Neither any unexpected bleeding during surgery nor any post-op hematoma or urinary complications were observed in participants.

DISCUSSION

Lateral pelvic lymphadenectomy is one of the treatments for patients suffering from advanced low rectal cancer. However, a universal agreement about its effectiveness is still lacking and there is no global agreement on whether lymph node dissection could be beneficial for low rectal cancer patients or not. Therefore, different approaches to such patients are used among surgeons worldwide. For instance, lateral pelvic lymphadenectomy is being used as a recommended treatment in Japan, while it is not frequently performed in western societies (6,11-13).

In the current study, we found tan estimated 12.5% for local recurrence in participants, which is consistent with previous studies reporting local recurrence rate in patients who had total mesorectal excision ranging from 5% to 40% (4,14-17). Yokoyama et al. have reported local recurrence in 3.0% of patients with LLND, while in patients without lymphadenectomy, it was 12.2% (18). The percentage of 1-year disease free survival for patients treated by TME and LLND and was 87.5% in our study. Although this

| Table 1. Characteristics of the study participants (n= 32) |
|----------------------------------------------------------|
| **Sex** | **Male** | 17 (53.1%) | 15 (46.8%) |
| **Female** | 15 (46.8%) |
| **Age** | **Mean (SD)** | 57.3 (13.9) |
| **Total number of dissected lymphnode** | **TME** | 279 |
| **LLND** | 232 |
| **Mean (per patient)** | 15.97 |
| **Total number of positive lymph node** | **TME** | 42 (15.0%) |
| **LLND** | 7 (3.0%) |
| **Mean (per patient)** | 1.53 |

SD: Standard deviation, TME: Total mesorectal excision, LLND: Lateral lymph node dissection.
number was partially higher in women than men, no statistically significant difference was observed. This finding is consistent with previously performed studies as well (19-21).

We examined 232 lateral lymph nodes, seven of which were positive for metastasis (3.0%). This finding is substantially lower compared to the previous studies, reporting lateral pelvic lymph node involvement from 38.0% to 71%. This could be the result of neoadjuvant chemoradiotherapy all of the studied patients received prior to surgery. We were unable to find any other attributable factors to the low number of positive lymph nodes in our cases. Therefore, this finding needs further testing in future studies. In addition, in recent studies, lateral lymph node (LLN) involvement rate has been reported 14.6% and 19.1% (Wu and Yokoyama), which is closer to our results (6,18). Positive LLN is associated with increased risk of local recurrence, which consequently reduces survival in advanced low rectal cancer patients (6). There is some evidence indicating that LLND provides better outcomes regarding both local recurrence and survival in patients diagnosed with negative lateral pelvic lymph nodes (6,7,18,19). Sugihara et al. have reported a significant difference in 5-year survival rate after surgery in patients with negative and positive lymph node dissection (7). Our current study also showed a significantly higher 1-year disease free survival rate in negative lymph node patients (95.5%) compared to patients with positive LLN (70%), which is compatible with previous studies (7,8).

Lymph node dissection is not a procedure without complication. It generally increases operation time and blood loss. Hence, patient selection for LLND must be regarded as an important factor to receive better results in terms of both local recurrence and survival rate in low rectal cancer patients (18).

We encountered some limitations in our study which should be considered while interpreting the results. First of all, small number of study participants along with short follow-up time might have resulted in overestimated survival rates in patients who had TME + LLND. Secondly, as the current study was a case-series, there was no comparison group. Therefore, we believe that the findings of this study should be reevaluated in future clinical trials, as there are alternative treatments for advanced low rectal cancer including mere TME and preoperative chemoradiotherapy.

In conclusion, it seems that TME with LLND could prolong survival and reduce local recurrence in patients with advanced mid and low rectal cancer as the results of current study support the effectiveness of lymphadenectomy in terms of survival improvement of mid and low rectal cancer patients.

ACKNOWLEDGEMENT

This study was supported by the Cancer Research Center of Iran Cancer Institute. The authors would like to thank all study participants and all of our colleagues at the Iran Cancer Institute who helped us in data collection.
Ethics Committee Approval: The methodology of the study was reviewed and approved by the medical ethics committee of Tehran University of Medical Science (Approval ID: IR.TUMS.VCR.REC.1397.629-Certificate available on demand).

Informed Consent: Written informed consent was obtained from patient who participated in this case.

Peer-review: Externally peer-reviewed.

Author Contributions: Concept - H.M.; Design - H.M., A.B.; Supervision - H.M., R.O.; Materials - A.B.; Data Collection and/or Processing - A.B., M.A.B., Analysis and/or Interpretation - A.B.; Literature Search - M.A.B.; Writing Manuscript – A.B.; Critical Reviews – R.O., H.M.

Conflict of Interest: No conflict of interest was declared by the authors.

Financial Disclosure: The authors declared that this study has received no financial support.

REFERENCES
1. Laurent C, Nobili S, Rullier A, Vendrely V, Saric J, Rullier E. Efforts to improve local control in rectal cancer compromise survival by the potential morbidity of optimal mesorectal excision. J Am Coll Surg 2006; 203 (5): 684-91. [CrossRef]
2. Liang Y, Qing S, Ding W, Chen P, Huang Y, Yu H. Total mesorectal excision versus conventional radical surgery for rectal cancer: a meta analysis. Zhonghua Wei Chang Wai Ke Za Zhi 2007; 10 (1): 43-8. [CrossRef]
3. Szynglarewicz B, Matkowski R, Forgacz J, Pudelko M, Smorag Z, Dryl J, et al. Clinical factors in prediction of prognosis after anterior resection with total mesorectal excision for carcinoma of the rectum. Oncol Rep 2007; 17 (2): 471-5. [CrossRef]
4. Piso P, Dahlke MH, Mirena P, Schmidt U, Aselmann H, Schlitt HU, et al. Total mesorectal excision for middle and lower rectal cancer: a single institution experience with 337 consecutive patients. J Surg Oncol 2004; 86 (3): 115-21. [CrossRef]
5. Lezoche E, Guerrieri M, De Sanctis A, Campagnacci R, Baldarelli M, Lezoche G, et al. Long-term results of laparoscopic versus open colorectal resections for cancer in 235 patients with a minimum follow-up of 5 years. Surg Endosc 2006; 20 (4): 546-53. [CrossRef]
6. Wu ZY, Wan J, Li JH, Zhao G, Yao Y, Du JL, et al. Prognostic value of lateral lymph node metastasis for advanced low rectal cancer. World J Gastroenterol 2007; 13 (45): 6048. [CrossRef]
7. Sugihara K, Kobayashi H, Kato T, Mori T, Mochizuki H, Kameoka S, et al. Indication and benefit of pelvic sidewall dissection for rectal cancer. Dis Colon Rectum 2006; 49 (11): 1663-72. [CrossRef]
Rektum kanseri hastalarında lateral lenf nodu diseksiyonunun terapötik sonuçlarının, lenf nodu oranının ve kısa-uzun dönem komplikasyonlarının değerlendirilmesi

Habibollah Mahmoodzadeh¹, Ramesh Omranipour¹, Anahita Borjian¹, Mohammad Amin Borjian¹

¹Tahran Tıp Bilimleri Üniversitesi, Kanser Enstitüsü, Tahran, İran

ÖZET

Giriş ve Amaç: Bu çalışmanın amacı, 2016-2018 yılları arasında İran Kanser Enstitüsünde total mezorektal eksizyon (TME) ve lateral lenf nodu diseksiyonu (LLND) geçiren ileri evre orta-alt rektum kanseri hastalarında (2-3. Evre) hastalıksız sağkalım, lenf nodu oranı (LNO) ve komplikasyon oranını değerlendirmektir.

Gereç ve Yöntem: Bu çalışma Mart 2016-Mart 2018 tarihleri arasında İran Kanser Enstitüsünde küratif cerrahi ve lateral lenf nodu diseksiyonu ile tedavi edilen 32 hasta üzerinde yürütüldü. Cinsiyete göre ikili klinik sonuçların dağılımını değerlendirmek için ki-kare testi kullanıldı. Ayrıca, %95 güven aralıklarına karşılık gelen bir yıllık hastalıksız sağkalımı hesaplamak için Kaplan-Meier yaklaşımında Breslow testi kullanıldı.

Bulgular: TME ile diske edilen 279 lenf nodundan 42 (mezorektal)'si ve LLND ile diske edilen 232 lenf nodundan yedisi (iliyak, para-iliyak ve obturator) metastaz için pozitif tespit edilmiştir. Kadınlara oranla (bir hasta) erkeklerde (üç hasta) daha yüksek oranla lokal nüks izlenmiştir ancak bu oran istatistiksel açıdan anlamamıştır (p= 0,878).icine istatistiksel olarak anlamlı olmasa da erkeklerde kısastta kadınlarda daha yüksek bir yıllık hastalıksız sağkalım oranı tespit edilmiştir (erkekler: %82,4, kadınlar: %93,3, p= 0,356). Negatif lenf nodu olan hastada bir yıllık hastalıksız sağkalım oranı %95.5 iken aynı oran pozitif lenf nodu olan hastalarda %70 idi (p= 0,047).

Sonuç: LLND ile TME, ileri evre alt rektum kanseri hastalarında lokal nüksü azaltabilir ve sağkalımını ustadabilir. Ancak, bu tür bir müdahaleyi İran'da standart tedavi olarak kabul etmek için büyük ölçüde klinik çalışmalara ihtiyaç vardır.

Anahtar Kelimeler: Rektal neoplazma, lenf nodu eksizyonu, sağkalım, kemoradyoterapi

DOI: 10.5578/turkjsurg.4593

Therapeutic results of lateral lymph node dissection in rectal cancer patients